Axa S.A. Exelixis, Inc. Transaction History

Axa S.A.

$32.2 Billion
Q4 2024

A detailed history of Axa S.A. transactions in Exelixis, Inc. stock. As of the latest transaction made, Axa S.A. holds 89,130 shares of EXEL stock, worth $3.28 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

89,130

Previous 13,141 578.26%

Holding current value

$3.28 Million

Previous $341,000 770.38%

% of portfolio

0.01%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$25.39 - $36.46 $1.93 Million - $2.77 Million	75,989 Added 578.26%	89,130 $2.97 Million
Q3 2024 Nov 14, 2024	SELL	$21.96 - $27.6 $6.11 Million - $7.68 Million	-278,274 Reduced 95.49%	13,141 $341,000
Q2 2024 Feb 25, 2025	BUY	$20.34 - $23.73 $4.11 Million - $4.8 Million	202,285 Added 226.96%	291,415 $6.55 Million
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $2.54 Million - $2.97 Million	-124,988 Reduced 30.02%	291,415 $6.55 Million
Q1 2024 May 15, 2024	BUY	$20.17 - $23.93 $2,339 - $2,775	116 Added 0.03%	416,403 $9.88 Million
Q4 2023 Jul 16, 2024	SELL	$19.25 - $24.13 $2,233 - $2,799	-116 Reduced 0.03%	416,287 $9.99 Million
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $193,847 - $242,989	-10,070 Reduced 2.36%	416,287 $9.99 Million
Q3 2023 Nov 14, 2023	SELL	$19.04 - $22.74 $1.87 Million - $2.23 Million	-97,981 Reduced 18.69%	426,357 $9.32 Million
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $131,096 - $147,763	7,215 Added 1.4%	524,338 $10 Million
Q1 2023 May 15, 2023	SELL	$16.3 - $19.41 $139,039 - $165,567	-8,530 Reduced 1.62%	517,123 $10 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $3.17 Million - $3.68 Million	211,749 Added 67.46%	525,653 $8.43 Million
Q3 2022 Feb 14, 2023	BUY	$15.68 - $22.27 $1.14 Million - $1.62 Million	72,894 Added 30.25%	313,904 $4.92 Million
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $1.14 Million - $1.62 Million	72,894 Added 30.25%	313,904 $4.92 Million
Q2 2022 Feb 14, 2023	SELL	$17.44 - $23.16 $4.89 Million - $6.5 Million	-280,492 Reduced 53.79%	241,010 $5.02 Million
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $4.89 Million - $6.5 Million	-280,492 Reduced 53.79%	241,010 $5.02 Million
Q1 2022 Feb 14, 2023	BUY	$17.03 - $22.67 $3.54 Million - $4.71 Million	207,598 Added 66.13%	521,502 $11.8 Million
Q1 2022 May 13, 2022	BUY	$17.03 - $22.67 $85 - $113	5 Added 0.0%	521,502 $11.8 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $97,178 - $134,233	6,135 Added 1.19%	521,497 $9.53 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $233,448 - $302,767	14,322 Added 2.86%	515,362 $10.9 Million
Q2 2021 Aug 13, 2021	SELL	$17.95 - $25.56 $2.16 Million - $3.07 Million	-120,196 Reduced 19.35%	501,040 $9.13 Million
Q1 2021 May 14, 2021	BUY	$20.53 - $25.22 $1.4 Million - $1.72 Million	68,061 Added 12.3%	621,236 $14 Million
Q4 2020 Feb 12, 2021	SELL	$18.39 - $24.8 $2.24 Million - $3.02 Million	-121,591 Reduced 18.02%	553,175 $11.1 Million
Q3 2020 Nov 13, 2020	SELL	$20.67 - $26.94 $3.02 Million - $3.94 Million	-146,224 Reduced 17.81%	674,766 $16.5 Million
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $13.5 Million - $22.5 Million	820,990 New	820,990 $19.5 Million
Q4 2017 Feb 13, 2018	SELL	$24.23 - $30.93 $4.86 Million - $6.2 Million	-200,400 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$23.35 - $29.24 $4.68 Million - $5.86 Million	200,400	200,400 $4.86 Million

Others Institutions Holding EXEL

# of Institutions

566

Shares Held

251M

Call Options Held

1.45M

Put Options Held

1.13M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.8B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account